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Although growth factors and anti-apoptotic peptides have been shown to be neuroprotective 
in stroke models translation of these experimental findings to clinic is hampered by limited 
penetration of peptides to the brain. Here, we show that a large peptide like the basic 
fibroblast growth factor (bFGF) and a small peptide inhibitor of caspase-3 (z-DEVD-FMK) 
can effectively be transported to the brain after systemic administration by incorporating 
these peptides to brain-targeted nanoparticles. Chitosan NPs were loaded with peptides and 
then functionalized by conjugating with antibodies directed against the transferrin receptor-1 
on brain endothelia to induce receptor-mediated transcytosis across the blood-brain barrier. 
Pre-ischemic systemic administration of bFGF- or z-DEVD-FMK-loaded nanoparticles 
significantly decreased the infarct volume after 2-h middle cerebral artery occlusion and 22-h 
reperfusion in mice. Co-administration of bFGF- or z-DEVD-FMK-loaded nanoparticles 
reduced the infarct volume further and provided a 3-h therapeutic window. bFGF-loaded NPs 
were histologically detected in the brain parenchyma and also restored ischemia-induced Akt 
dephosphorylation. The neuroprotection was not observed when receptor-mediated 
transcytosis was inhibited with imatinib or when bFGF-loaded nanoparticless were not 
conjugated with the targeting antibody. Nanoparticles targeted to brain are promising drug 
carriers to transport large as well as small BBB-impermeable therapeutics for neuroprotection 
against stroke. 






Recent research has disclosed that cell death in acute as well as chronic 
neurodegenerative diseases involves common mechanisms such as caspase activation1-5. 
Therefore, inhibitors of caspases (e.g. Benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-
Asp(OMe)-fluoromethylketone; z-DEVD-FMK) appear to be attractive therapeutic targets 
for a wide range neurological diseases including stroke6-8. Unfortunately, most of the 
inhibitor agents are small peptides that cannot cross the BBB. On the other hand, growth 
factors (e.g. basic fibroblast growth factor; bFGF) suppress cell death by acting at several 
points on death pathways and, additionally, promote regeneration9-11. These features make 
them promising agents for treatment of stroke and other neurodegenerative diseases. 
Unfortunately, these large peptides too cannot penetrate the brain tissue when systemically 
administrated. Although it has been proposed that opening of the BBB after ischemia could 
allow large molecules such as bFGF could enter the brain, recent studies examining the BBB 
leakage topographically have shown that early leakage is only seen in the deeply ischemic 
core areas but not in the potentially salvageable penumbra.12, 13, 14 
Promoting cell survival while inhibiting death effectors is a potentially promising 
neuroprotective approach that may provide additive synergy between these two groups of 
drugs. Indeed, Ma et al. demonstrated that both z-DEVD-FMK and bFGF could reduce 
infarct size when given intracerebroventricularly and that their combined administration had 
a synergistic effect; not only the infarct reduction was greater but also the therapeutic time 
window was prolonged compared to their individual use15. Therefore, the development of an 
effective brain delivery system for peptides is needed to translate these promising 
experimental achievements to clinic. 
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Brain-targeted nanoparticles (NPs) can transport large amounts of BBB-impermeable 
agents across the BBB on systemic administration16, 17. We previously demonstrated that 
chitosan NPs loaded with z-DEVD-FMK and conjugated with anti-transferrin receptor-1 
monoclonal antibody (TfRMAb) rapidly crossed the BBB upon systemic administration to 
mice by way of transferrin receptor-mediated transcytosis and, provided neuroprotection 
against focal cerebral ischemia18. However, loading large peptides such as bFGF to NPs and 
their transport to the brain in an active form and sufficient concentrations remained a 
challenge.  In the present study, we have first developed the conditions to load bFGF to 
chitosan NPs and then showed that they reduced ischemic injury on systemic administration. 
Next, we investigated if we could obtain an additive protective activity by combined 
administration of z-DEVD-FMK and bFGF-loaded NPs and, whether or not this approach 
could provide a prolonged therapeutic window. We have also demonstrated activation of the 
downstream pathways in bFGF signaling to confirm that bFGF was transported in sufficient 
concentrations similar to the inhibition of caspase-3 activity with z-DEVD-FMK-loaded NPs 
as we previously showed18. Finally, we verified that neuroprotection was mediated by 
transcytosis of peptide-loaded NPs across the endothelium by inhibiting transcytosis with 
imatinib19. Importantly, the targeted brain delivery of bFGF-loaded NPs provided not only 
neuroprotection but also about 300 times reduction in the amount of the peptide administered 
to the mouse compared to the systemic administration of plain bFGF, offering a great 
advantage to reduce systemic adverse effects20. 
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MATERIALS AND METHODS 
Preparation and characterization of the TfRMAb-conjugated or unconjugated chitosan 
NPs and, evaluation of z-DEVD-FMK and bFGF release from them are given elsewhere11. 
Briefly, NPs were prepared by loading either peptide to chitosan-polyethyleneglycol-biotin 
graft polymers in a process aided by reticulation with pentasodium tripolyphosphate. 
Polyethyleneglycol chains were added to the NP surface to reduce clearance by the 
reticuloendothelial system, whereas biotin was used to conjugate streptavidinylated anti-
transferrin receptor-1 monoclonal antibody by way of streptavidin-biotin binding. These 
procedures yielded NPs in sizes of 715±32 and 747±42 nm when z-DEVD-FMK or bFGF 
were loaded, respectively. 
The experiments were performed on 75 Swiss albino, male mice (25-30 g). The study 
protocol was approved by the Hacettepe University Animal Experiments Local Ethics 
Committee (2008/78-1). Focal cerebral ischemia was induced with the intraluminal filament 
middle cerebral artery occlusion (MCAo) method as described previously21. Briefly, animals 
were anesthetized with 2% isoflurane and maintained on 1.5% isoflurane and 30% oxygen. 
After ligating the right common carotid and external carotid arteries, a nylon filament (8-0) 
inserted into the common carotid artery was advanced to the origin of MCA. The distal 3 mm 
of filaments was coated with silicone resin/hardener mixture. For reperfusion, the filament 
was withdrawn. The regional cerebral blood flow (rCBF) in ischemic area was measured by 
laser-Doppler flowmetry. Rectal temperature was maintained at 37.0±0.5C with a 
homeothermic blanket. Systolic blood pressure was measured noninvasively. Tissue oxygen 
saturation was monitored from the paw by a pulse oximeter (V3304 Tabletop Pulse 
Oximeter; Surgivet). 
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 Seven groups of mice were subjected to 2 h proximal MCAo and 22 h reperfusion. 
Animals were randomly allocated to study groups in blocks. Fifteen years of experience of 
our lab shows that this stroke model in Swiss albino mice results in an infarct volume of 50±6 
mm3 (mean±SD). Based on a previous study15 demonstrating neuroprotection by 
intracerebroventricular administration of caspase inhibitors and bFGF against 2 h MCA 
occlusion in mice, we anticipated a decrease in infarct size by at least 20% in our model. 
Accordingly, sample size calculation indicated that six animals were required per group for 
80% power and a α of 0.05. The control group received an equal mixture of non-
functionalized (TfRMAb-free) NPs loaded with z-DEVD-FMK  (240 ng) or bFGF (17 ng). 
Treatment groups received functionalized (TfRMAb-conjugated) NPs loaded with z-DEVD-
FMK (240 ng) or bFGF (17 ng) or an equal mixture of both. NPs were administered just 
before inducing ischemia in these groups. The combined treatment was given to another 
group 3 h post-ischemia. NPs were administered intraperitoneally in 0.1 ml ultrapure water in 
the above groups. To compare the efficacy of intravenous and intraperitoneal administrations, 
another group was treated intravenously with bFGF-loaded NPs in 0.1 ml ultrapure water 
pre-ischemia.  Finally, mice treated with imatinib (150 mg/kg twice a day for 2 days) before 
the day of the MCAo were administered functionalized bFGF-loaded NPs (i.p.) pre-ischemia. 
Details of the groups and treatments are given in Table 1. 
 Motor functions were scored as described previously22. Twenty-two hours after 
reperfusion, prior to sacrifice, clinical motor functions were assessed and scored in each 
animal as: grade 0: no observable motor deficit (normal); grade I: failure to extend left 
forepaw on lifting the whole body by the tail (mild); grade II: circling to the contralateral side 
(moderate); grade III: leaning to the contralateral side at rest or no spontaneous motor activity 
(severe). One of the 2 evaluators was blinded with respect to the study groups and, only the 
values agreed on by both investigators were analyzed.  
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Mice were then anesthetized with a lethal dose of chloral hydrate (1 g/kg, i.p.), 
transcardially perfused with 100 ml of heparinized saline (10 IU/ml) followed by 4% 
paraformaldehyde and then decapitated. Brains were stored in 4% paraformaldehyde for 24 
hours, after which 2-mm thick 5 brain slabs were serially cut in coronal plane and embedded 
in paraffin. Five μm-thick sections were obtained from the posterior surface of each slab and, 
stained with hematoxylin and eosin. To calculate the infarct volume the boundary of infarct 
area, characterized by reduced eosin staining on hematoxylin and eosin-stained coronal 
sections under light microscopy was outlined with image analysis software (ImageJ 1.44o). 
The size of infarcted area in each section was calculated by subtracting the non-infarcted 
region in the ischemic hemisphere from the total surface area of the contralateral hemisphere. 
The infarct volume was then calculated by multiplying each sequential infarct area by the 
distance between sections (2 mm) and by 5 (the number of sections from each brain).  
In another set of animals, brains were examined to illustrate the NPs penetrated into 
parenchyma. Ten naïve mice were given functionalized bFGF-loaded NPs (pre-ischemia, i.p. 
or i.v.) 30 min (n=2), 1 h (n=2) and 3 h (n=6) before sacrifice. Mice administered non-
functionalized bFGF-loaded NPs served as controls (n=3). NPs were also searched in brain 
sections of 4 mice subjected to 2 h ischemia and 1 h reperfusion and, received functionalized 
(n=2) or non-functionalized (n=2) bFGF-loaded NPs. Two mice given the vehicle of NP 
suspensions (0.1 ml ultrapure water, i.p.) served as sham controls. NPs in sections were 
detected by either labeling free biotin molecules on the NP surface with streptavidin–
horseradish peroxidase or immunolabeling against the human bFGF loaded to NPs.  
For conjugating streptavidin to biotin molecules decorating the NP surface, 4-5 µm-
thick coronal sections were prepared from the paraffin-embedded blocks. Sections were 
deparaffinized at 60oC overnight and then in xylene for one hour. Sections were hydrated in 
graded alcohol solutions, washed in PBS for 10 min and then treated with streptavidin-
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horseradish peroxidase complex (Reagent C of Acu-Stain Mouse+Rabbit HRP Kit, Genemed 
Biotechnologies, CA, USA) for 1 h at room temperature. After three 10-min washes with 
PBS, sections were treated with filtered diaminobenzidine (DAB) (Genemed 
Biotechnologies, CA, USA) for 1 h at room temperature. Sections were cover-slipped with 
Hoechst 33258 following three 10-min washes with PBS 
For immunolabeling, paraffin-embedded 4-5 µm-thick sections were deparaffinized 
and hydrated in xylol and graded alcohol solutions. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxidase solution. Antigen retrieval was performed with 10 
mmol/L citrate buffer (pH=6) in a pressure cooker for 20 minutes. The sections were then 
rinsed with PBS (pH 7.4) at room temperature and nonspecific binding was blocked by using 
3% bovine serum albumin (Sigma, USA) in PBS for 20 minutes. Next, the sections were 
incubated with anti-human-FGF-2 / basic FGF polyclonal antibody (Millipore, 1:100 in PBS) 
at room temperature for 1 hour. Immunodetection of bFGF was performed using the 
conventional streptavidin–horseradish peroxidase technique (Dako cytomation kit, CA, 
USA). Filtered DAB (Sigma, St Louis, Missouri, USA) was used as chromogen. Negative 
controls were carried by omitting the primary antibody. 
In another set of animals, brain samples of the MCA area from mice subjected to 2 h 
ischemia and 22 h reperfusion and received (i.v.) either functionalized NPs (n=6) or non-
functionalized NPs loaded with bFGF (n=4) as well as from sham-operated naïve mice (n=4) 
were used for the blotting procedure. Samples obtained by wedge resection of the MCA area 
were placed on ice and lysed in RIPA buffer (25 mM Tris–HCl (pH 7.6), 150 mM NaCl, 1% 
Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) with protease (Sigma) and 
phosphatase inhibitors (Sigma) by ultrasonic homogeniser (Bandelin Sonopuls). The lysates 
were centrifuged at 14000 RPM for 15 minutes at 4°C. The supernatants were collected and 
protein concentrations of the samples were determined by Qubit Protein Assay Kit 
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(Invitrogen). Equal amounts of protein were loaded to 4-12% SDS-PAGE (Invitrogen), and 
subsequently transferred to PVDF membranes (Invitrogen) by iBlot dry blotting system 
(Invitrogen). Nonspecific protein binding was blocked by incubating the PVDF membranes 
in 3% BSA (Sigma) in TBS-T for 1 hour at 4°C, and then the membranes were incubated 
with anti-rabbit phospho-Akt (Ser473) antibody (1:1000, Cell Signaling Technology) and 
anti-rabbit Akt antibody (1:1000, Cell Signaling Technology) overnight at 4°C. Next day, 
after washing with TBS-T, the membranes were incubated with horseradish peroxidase-
conjugated anti-rabbit IgG secondary antibody (1:3000, Cell Signaling) for 1 hour at room 
temperature. The protein bands were visualized by chemiluminescence (Super Signal West-
Femto; Pierce). Membranes were stripped and re-probed for anti-rabbit beta-tubulin (1:7500, 
Sigma) in order to normalize p-Akt to Akt band intensities on different gels. Images were 
captured by Kodak 4000MM image station. ImageJ was used for data analysis. 
Statistical analysis 
 Data are expressed as meanSEM. Blood pressure, rCBF, tissue oxygen saturation, 
motor function scores; infarct volumes and p-Akt/Akt ratios of groups were compared with 
Kruskal–Wallis test. Statistically significant data were further analyzed with Mann–Whitney 
U test. The infarct volumes (parametric values) were correlated with the neurological deficit 
scores (non-parametric values) by using Spearman's test. A p value of  0.05 was regarded as 
statistically significant. P values were corrected for multiple comparisons. 
 
RESULTS 
Systemically administered peptide-loaded NPs provide neuroprotection 
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For neuroprotection study, mice were randomly allocated to 7 groups of 6 animals to 
avoid any selection bias. The mean (±SEM) infarct volume of the control group receiving 
non-functionalized NPs loaded with an equal mixture of bFGF or z-DEVD-FMK, which can 
release bFGF and z-DEVD-FMK to the plasma but are unable to cross BBB, was 51±1 mm3 
after 2h MCAo and 22h reperfusion (Figure-1A). In contrast, functionalized bFGF-loaded 
NPs significantly decreased the infarct volume when administered either i.v. (37±3 mm3) or 
i.p. (33±1 mm3) (Figure-1A, C). z-DEVD-FMK-loaded, functionalized NPs (i.p.) also 
reduced the infarct size (37±3 mm3) similarly to when they were administered i.v., as 
previously reported18. Administration of an equal mixture of bFGF- or z-DEVD-FMK-
loaded, functionalized NPs further reduced the infarct volume to 24±2 mm3 (n=5, one animal 
from this group was excluded because we detected ischemic changes also in the contralateral 
hemisphere). To test if the neuroprotection observed with the pre-ischemic treatments above 
might have clinical significance, an equal mixture of bFGF- and z-DEVD-FMK-loaded NPs 
was administered 3 hours after stroke (1 h after reperfusion), which also significantly reduced 
the infarct volume to 34±2 mm3. Treatments with NPs improved motor function deficit 
scores parallel to the reductions in infarct size although the decreases in deficit scores were 
less striking possibly because some sensorimotor fibers ascending to or descending from the 
recovered cortex could not escape damage in the ischemic subcortical area (Figure-1B). 
However, we found a moderate but statistically significant correlation (r=0.59, p=0.001, 
n=29) between the infarct volumes and the neurological deficit scores. 
To confirm that the neuroprotection provided by NPs is mediated by peptides 
transported into brain parenchyma, we treated another group of mice with imatinib, which 
inhibits the receptor-mediated endothelial transcytosis, two days prior to administering NPs19. 
Imatinib treatment suppressed the neuroprotective effect of bFGF-loaded functionalized NPs; 
the infarct volume of this group (49±2 mm3, n=5, one mouse allocated to this group died 
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during surgery) was not significantly different than the control group receiving non-
functionalized NPs (Figure-1D). These mice slightly lost weight (3±0 g in 2 days); however, 
we did not detect any histological abnormalities in brain endothelia or other vascular 
structures or in parenchyma in non-ischemic hemispheres by light microscopy as reported21. 
Since no significant differences in rCBF changes, arterial blood pressure and tissue 
oxygen saturation were observed between groups during ischemia (Table 2), we attributed the 
reduction in infarct	 volume and motor function to neuroprotective action of the brain-
delivered peptides but not to any potential hemodynamic or systemic changes induced by 
circulating NPs. Moreover, to verify that effective concentrations of bFGF in the parenchyma 
were achieved, we measured the phosphorylation level of Akt (a downstream step in bFGF 
signaling) in wedge-shaped	 ischemic MCA territory specimens in 14 mice. p-Akt/Akt ratio 
significantly dropped to 39±4% in mice subjected to 2 h ischemia and 22 h reperfusion and 
treated with non-functionalized NPs (n=4) compared to 66±3% in non-ischemic, sham-
operated mice brains (n=4, p<0.05). Treatment with functionalized NPs restored the p-
Akt/Akt ratio in ischemic brain specimens near to sham-operated brain levels (60±9%, n=6, 
p=0.61)(Figure-2). Of note, effective inhibition of caspase-3 activity in ischemic mouse brain 
with z-DEVD-FMK-loaded NPs given at the same dose used in the present study had 
previously been shown18. 
Detection of NPs in brain parenchyma  
Investigators blinded to the treatment evaluated the brain sections to detect NPs in 
parenchyma in 19 mice (Figure-3). NPs were scattered throughout the brain parenchyma and 
as the mice were thoroughly perfused before sacrifice, none was found inside vessel lumens 
except a few adhered to the endothelium. Numerous parenchymal NPs were detected 30 min 
and 1h after administration, decreasing by 3 h. This observation conforms to the time profile 
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of NP penetrance to the brain parenchyma by way of transferrin receptor-mediated 
transcytosis as detected with in vivo brain imaging in intact mice under anesthesia18. Since 
NPs could unambiguously be detected only at 1500X magnification, quantification of their 
distribution across 5 µm-thick sections was not feasible and, hence, was limited by sampling 
error; nevertheless, NPs appeared to be similarly distributed in ischemic as well as non-
ischemic hemispheres with visual screening. In contrast, we did not observe any NPs in brain 
parenchyma (including the ischemic hemisphere) of the mice given non-functionalized NPs, 
excluding the possibility that NPs could penetrate the brain through the ischemia-damaged 
BBB in accordance with the neuroprotection and biochemistry data. NPs had a clearly 
distinguishable spherical shape (less than 1 µm) when visualized with the streptavidin-
horseradish peroxidase technique exploiting the presence of free biotin molecules on the NP 
surface (Figure-3A). The specificity of this labeling was further confirmed by 
immunostaining of bFGF peptides loaded to the NPs with anti-bFGF antibodies (Figure-3C). 
There was no evidence of inflammation or astrocyte end-feet swelling in the non-ischemic 
brain parenchyma around the NPs, conforming with the idea that chitosan is a biocompatible 
polymer and does not induce tissue toxicity at microscopic level23. 
DISCUSSION 
In this study, we demonstrated that (I) a relatively large peptide like bFGF (17.2 kDa) 
can be successfully encapsulated into chitosan NPs and targeted to the brain as well as z-
DEVD-FMK, a small peptide consisting of four amino acids; (II) systemically administered 
NPs can transport bFGF to the brain rapidly, efficiently and, importantly, in an active form, 
which provides significant neuroprotection against stroke induced by 2 hours of MCAo; (III) 
this effect can totally be suppressed by inhibition of transcytosis across the BBB; (IV) 
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combined treatment with z-DEVD-FMK- and bFGF-loaded NPs provides additive 
neuroprotective effect and, is effective even when administered 3 hours post-ischemia. 
 The active substances encapsulated to NPs were composed of amino acids. Therefore, 
during preparation of NPs, we chose mild chemical conditions to preserve their three 
dimensional structures and functional groups24. Indeed, both peptides were found to be 
biologically active in the brain after systemic administration (see also18). Systemically 
administered bFGF-loaded NPs showed neuroprotection only when they were conjugated 
with antibodies against the TfR-1 located on the brain vascular endothelium. This excludes 
the possibilities that bFGF released from the NPs to circulation or direct access of bFGF-
loaded NPs to the brain through the ischemia-damaged BBB may have provided 
neuroprotection and, strongly suggests that transcytosis of NPs mediated by the TfR-1 is the 
main mechanism transporting bFGF into the brain parenchyma. This idea was further 
supported by complete suppression of the neuroprotection after inhibiting endothelial 
transcytosis with imatinib19, 25. Despite unambiguous microscopic and pharmacological 
evidence (i.e. neuroprotection) provided by previous studies18, 26, we did not exclude the 
possibility that the infarct sparing effect might have been secondary to an endothelial action 
of the peptides (e.g. as proposed for systemically administrated bFGF27). The present study 
with imatinib, which allows penetration into the endothelium but disrupts transcytosis by 
inhibiting the exocytosis from the endothelium to parenchyma, convincingly shows that, for 
neuroprotection, NPs must be exocytosed from the endothelium to the brain parenchyma and 
that an endothelial action alone is not sufficient19. We should emphasize that the total amount 
of bFGF that we administered to a mouse with NPs is too small (680 ng/kg) compared to the 
dose (200 µg/kg i.v.) used in studies reporting neuroprotection with systemically 
administered bFGF to the mouse20, supporting the idea that rather than bFGF spilled to 
plasma from NPs, bFGF transported to the brain provides neuroprotection, possibly by 
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achieving parenchymal concentrations comparable to that obtained with i.c.v. injection of 30 
ng of bFGF in the study by Ma and his colleagues15. Rich and selective expression of TfR1 
on brain vasculature unlike the TfR2 subtype expressed in other tissues may have facilitated 
preferential targeting of TfR1MAb-conjugated NPs to the brain. Therefore, targeted delivery 
of bFGF to the brain not only provides neuroprotection but also reduces the possibility of 
systemic side effects by reducing the amount of bFGF administered about 300 times. Finally, 
we should note that the administration of nanoparticles either before inducing ischemia when 
circulation was still intact or 1 h after reperfusion when the ischemic tissue was at least partly 
reperfused must have allowed distribution and transport of nanoparticles to all MCA territory. 
The collateral blood flow to the penumbra must have further sustained the delivery during 2 
hours of MCA occlusion. 
Earlier work from our group demonstrated that chitosan NPs loaded with small 
peptides are rapidly transported into the brain when they were functionalized with 
TfRMAb18, 26. The neuroprotection observed and the activation of the brain bFGF-p-Akt 
pathway in the present study further illustrate that they can efficiently carry large peptides to 
the brain as well. This finding is important from a technological viewpoint because it shows 
that encapsulating large molecules does not unfavorably modify NP transport kinetics and 
that the preparation procedures used do not lead to loss of the peptide activity, which is 
extremely vulnerable to minor alterations in the 3D structure or to modifications by small 
molecules. Importantly, the peptides were also neuroprotective when co-administered 3 h 
after ischemia onset. This conforms to the 3-hour therapeutic window detected after their 
intracerebroventricular co-administration15 and, suggests that a significant amount of the 
loaded peptide must have been released from NPs in this time window. It is likely that, once 
inside the brain parenchyma, peptides are rapidly released from the NPs due to degradation of 
chitosan by enzymatically active forms of human chitinases such as the acidic mammalian 
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chitinase (AMCase), the di-N-acetylchitobiase and chitotriosidase23. Supporting this, 
histologically detectable NPs in parenchyma were decreased 3 h after administration. The 
upper limit of the therapeutic time window remains to be detected by future studies, as the 
main aim of the present extensive study was to replicate with systemically administered NPs 
the neuroprotection and synergy obtained with i.c.v. injection of bFGF and z-DEVD 3 h post-
ischemia. The present study also shows that co-administration of NPs loaded with different 
agents is a viable strategy to obtain additive effects and, technically, is a more practical 
approach than incorporating multiple agents into the same NP. Therefore, NPs loaded with 
several other protease inhibitors and survival factors shown to be neuroprotective in stroke 
models can be combined for more effective suppression of cell death mechanisms without 
inducing systemic toxicity28.  
In conclusion, chitosan NPs targeted to the brain appear to be promising drug carriers 
to transport large as well as small BBB-impermeable therapeutic agents. They are easy to 
prepare, rapidly transported to the brain, readily release their content without loss of activity, 
allow combination of different agents and, do not have any gross toxicity. Therefore, these 
exciting findings warrant further research to translate the developments to clinical 
applications. 
Conflict of Interest: We do not have any conflict of interest. 
Acknowledgement: Turgay Dalkara’s work is supported by the Turkish Academy of 
Sciences. This study is supported by The Scientific and Technological Research Council of 
Turkey (TUBITAK, Project Number: 109S017).
	 16
REFERENCES 
1.	 Asahi	 M,	 Hoshimaru	 M,	 Uemura	 Y,	 Tokime	 T,	 Kojima	 M,	 Ohtsuka	 T,	 et	 al.	
Expression	of	 interleukin‐1	beta	converting	enzyme	gene	family	and	bcl‐2	gene	
family	 in	 the	 rat	 brain	 following	 permanent	 occlusion	 of	 the	 middle	 cerebral	
artery.	J	Cereb	Blood	Flow	Metab.	1997;	17:11‐18	
2.	 Chen	 J,	Nagayama	T,	 Jin	KL,	 Stetler	RA,	 Zhu	RL,	Graham	SH,	 et	 al.	 Induction	 of	
caspase‐3‐like	 protease	 may	 mediate	 delayed	 neuronal	 death	 in	 the	
hippocampus	 after	 transient	 cerebral	 ischemia.	 Journal	of	Neuroscience.	 1998;	
18:4914‐4928	
3.	 Namura	S,	Zhu	 J,	Fink	K,	Endres	M,	Srinivasan	A,	Tomaselli	KJ,	 et	al.	Activation	




5.	 Dericioglu	N,	 Soylemezoglu	F,	Gursoy‐Ozdemir	Y,	Akalan	N,	 Saygi	 S,	Dalkara	T.	
Cell	 death	 and	 survival	 mechanisms	 are	 concomitantly	 active	 in	 the	
hippocampus	 of	 patients	 with	 mesial	 temporal	 sclerosis.	 Neuroscience.	 2013;	
237:56‐65	
6.	 Hara	H,	Friedlander	RM,	Gagliardini	V,	Ayata	C,	Fink	K,	Huang	Z,	et	al.	Inhibition	








10.	 Dawbarn	 D,	 Allen	 SJ.	 Neurotrophins	 and	 neurodegeneration.	Neuropathol	Appl	
Neurobiol.	2003;	29:211‐230	
11.	 Caban	 S,	 Capan	 Y,	 Couvreur	 P,	 Dalkara	 T.	 Preparation	 and	 characterization	 of	
biocompatible	 chitosan	 nanoparticles	 for	 targeted	 brain	 delivery	 of	 peptides.	
Methods	Mol	Biol.	2012;	846:321‐332	
12.	 Taheri	 S,	 Candelario‐Jalil	 E,	 Estrada	 EY,	 Rosenberg	 GA.	 Spatiotemporal	
correlations	 between	 blood‐brain	 barrier	 permeability	 and	 apparent	 diffusion	
coefficient	in	a	rat	model	of	ischemic	stroke.	PloS	ONE.	2009;	4:e6597	
13.	 Knowland	 D,	 Arac	 A,	 Sekiguchi	 KJ,	 Hsu	 M,	 Lutz	 SE,	 Perrino	 J,	 et	 al.	 Stepwise	




successful	 opening	 of	 an	 occluded	 cerebral	 artery.	 Nature	 medicine.	 2009;	
15:1031‐1037	
15.	 Ma	 J,	 Qiu	 J,	 Hirt	 L,	 Dalkara	 T,	 Moskowitz	 MA.	 Synergistic	 protective	 effect	 of	
caspase	 inhibitors	 and	 bfgf	 against	 brain	 injury	 induced	 by	 transient	 focal	
ischaemia.	Br	J	Pharmacol.	2001;	133:345‐350	
16.	 Kreuter	 J.	 Nanoparticulate	 systems	 for	 brain	 delivery	 of	 drugs.	Adv	Drug	Deliv	
Rev.	2001;	47:65‐81	
	 17
17.	 Nicolas	 J,	 Mura	 S,	 Brambilla	 D,	 Mackiewicz	 N,	 Couvreur	 P.	 Design,	
functionalization	 strategies	 and	 biomedical	 applications	 of	 targeted	
biodegradable/biocompatible	 polymer‐based	 nanocarriers	 for	 drug	 delivery.	
Chem	Soc	Rev.	2013;	42:1147‐1235	
18.	 Karatas	 H,	 Aktas	 Y,	 Gursoy‐Ozdemir	 Y,	 Bodur	 E,	 Yemisci	 M,	 Caban	 S,	 et	 al.	 A	
nanomedicine	 transports	 a	 peptide	 caspase‐3	 inhibitor	 across	 the	 blood‐brain	
barrier	and	provides	neuroprotection.	J	Neurosci.	2009;	29:13761‐13769	
19.	 Armulik	 A,	 Genove	 G,	 Mae	 M,	 Nisancioglu	 MH,	 Wallgard	 E,	 Niaudet	 C,	 et	 al.	
Pericytes	regulate	the	blood‐brain	barrier.	Nature.	2010;	468:557‐561	
20.	 Huang	 Z,	 Chen	 K,	 Huang	 PL,	 Finklestein	 SP,	 Moskowitz	 MA.	 bFGF	 ameliorates	










24.	 Amidi	 M,	 Romeijn	 SG,	 Borchard	 G,	 Junginger	 HE,	 Hennink	 WE,	 Jiskoot	 W.	
Preparation	 and	 characterization	 of	 protein‐loaded	 n‐trimethyl	 chitosan	
nanoparticles	as	nasal	delivery	system.	J	Control	Release.	2006;	111:107‐116	
25.	 Venalis	 P,	Maurer	 B,	 Akhmetshina	 A,	 Busch	 N,	 Dees	 C,	 Sturzl	M,	 et	 al.	 Lack	 of	
inhibitory	effects	of	 the	anti‐fibrotic	drug	 imatinib	on	endothelial	cell	 functions	
in	vitro	and	in	vivo.	J	Cell	Mol	Med.	2009;	13:4185‐4191	
26.	 Aktas	Y,	Yemisci	M,	Andrieux	K,	Gursoy	RN,	Alonso	MJ,	Fernandez‐Megia	E,	et	al.	
Development	 and	 brain	 delivery	 of	 chitosan‐peg	 nanoparticles	 functionalized	





28.	 Kilinc	 M,	 Gursoy‐Ozdemir	 Y,	 Gurer	 G,	 Erdener	 SE,	 Erdemli	 E,	 Can	 A,	 et	 al.	
Lysosomal	rupture,	necroapoptotic	interactions	and	potential	crosstalk	between	









1) TfRMAb-free, control pre-ischemia, i.p. 
Equal mixture of TfRMAb-free 
NPs loaded with z-DEVD-FMK or 
bFGF  
2) z-DEVD-FMK pre-ischemia, i.p. 
TfRMAb-conjugated NPs loaded 
with z-DEVD-FMK  
3) bFGF pre-ischemia, i.p. 
TfRMAb-conjugated NPs loaded 
with bFGF  
4) bFGF and z-DEVD pre pre-ischemia, i.p. 
Equal mixture of TfRMAb-
conjugated NPs loaded with z-
DEVD-FMK or bFGF 
5) bFGF and z-DEVD post 
3 hours post-
ischemia, i.p. 
Equal mixture of TfRMAb-
conjugated NPs loaded with z-
DEVD-FMK or bFGF 
6) bFGF i.v. pre-ischemia, i.v. 
TfRMAb-conjugated NPs loaded 
with bFGF  
7) bFGF + imatinib 
Imatinib; 150 mg/kg 
i.p. twice per day for 




TfRMAb-conjugated NPs loaded 
with bFGF  
	
Groups consist of 6 mice except groups 4 and 7 (n=5 in each). *z-DEVD-FMK (240 ng) or 




Table 2. Physiological parameters of groups 






TfRMAb-free, Control 937 (n=4) 293 961 
z-DEVD 954 (n=3) 272 942 
bFGF 905 (n=5) 283 971 
bFGF and z-DEVD    
(pre-ischemia) 
8310 (n=4) 303 962 
bFGF and z-DEVD     
(3 h post-ischemia) 
945 (n=3) 254 953 
bFGF (i.v.) 988 (n=5) 263 962 
bFGF+imatinib 94±3 (n=3) 28±4 96±1 
Values are given as meanSEM.  Group means were not significantly different (p>0.05). 
*Blood pressure could not be measured in some mice for technical reasons. Physiological 




Figure 1: The infarct volumes and motor function deficit scores of the control and treatment 
groups. Data are presented as mean±SEM. o: denotes individual values. A) After 2 h 
ischemia and 22 h reperfusion, infarct volumes of the groups receiving functionalized NPs 
loaded with z-DEVD-FMK, bFGF or an equal mixture of bFGF and z-DEVD-FMK 
decreased significantly compared with the group receiving non-functionalized NPs loaded 
with an equal mixture of bFGF and z-DEVD-FMK (TfRMAb-free, control). Combined 
treatment was more effective and had a 3-h therapeutic window.  B) Changes in motor 
function scores paralleled the infarct volume changes. C) i.p. or i.v. administration of 
functionalized NPs loaded with bFGF was equally effective in decreasing the infarct volume. 
D) When the endothelial transcytosis was inhibited with imatinib treatment, no 
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neuroprotection was obtained with bFGF-loaded functionalized NPs. * p<0.05 compared to 
the TfRMAb-free group. # p<0.05 compared to the bFGF or Z-DEVD-FMK-treated groups. 
The bFGF-NP (i.p.) group in C and TfRMAb-free group in D were reproduced from the data 
illustrated in A for comparison. 
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Figure 2: p-Akt/Akt Western blots of the MCA area of mice subjected to 2 h ischemia and 
22 h reperfusion. Akt phosphorylation (p-Akt/Akt ratio) decreased in the ischemic MCA area 
of the group treated with non-functionalized NPs (TfRMAb-free). Treatment with 
functionalized NPs (TfRMAb+) restored the p-Akt/Akt ratio close to the sham-operated brain 




Figure 3: Numerous NPs were penetrated to the brain (cortex) parenchyma 1 h after systemic 
administration of the functionalized NPs.  NPs were prepared by loading peptides (here, 
bFGF) to chitosan-polyethyleneglycol-biotin graft polymers and, were functionalized by 
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conjugating streptavidinylated anti-transferrin receptor-1 monoclonal antibody with 
streptavidin-biotin binding (A). The transmission electron micrograph in B illustrates a group 
of NPs in suspension; scale bar 2 µm. C; NPs in brain tissue were detected by binding 
streptavidin–horseradish peroxidase complex to free biotin molecules on the NP surface 
(NPs). D; Human bFGF molecules on the surface of NPs were also visualised with anti-
human bFGF antibody (arrows). Non-functionalized NPs did not penetrate to parenchyma (E, 
F). Anti-human bFGF antibody has cross reactivity to the mouse bFGF, hence, labeled the 
cortical cells, especially their nuclei, and caused a light background staining (D, F). In C and 
E, bright field images illustrating DAB labelling were superimposed with fluorescent images 
exhibiting Hoechst 33258-labeled nuclei of the same area to show cells nearby NPs. Scale 
bars: 20 μm. 
 
 
